<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311557</url>
  </required_header>
  <id_info>
    <org_study_id>Td519</org_study_id>
    <secondary_id>U1111-1115-6619</secondary_id>
    <nct_id>NCT01311557</nct_id>
  </id_info>
  <brief_title>Study of Adacel® Vaccine Administered to Persons 10 Years of Age</brief_title>
  <official_title>Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of study Td519 is to demonstrate that Adacel® vaccine (Tetanus Toxoid, Reduced
      Diphtheria Toxoid and Acellular Pertussis Adsorbed) is safe and immunogenic in persons 10
      years of age.

      Primary Objectives:

        -  To compare pertussis antibody responses induced by Adacel® in persons 10 to &lt;11 years of
           age to those induced by Adacel in persons 11 to &lt;12 years of age.

        -  To compare the booster responses against pertussis antigens induced by Adacel in persons
           10 to &lt;11 years of age to those induced by Adacel in persons 11 to &lt;12 years of age.

        -  To compare booster responses against tetanus and diphtheria induced by Adacel in persons
           10 to &lt;11 years of age to those induced by Adacel in persons 11 to &lt;12 years of age.

      Secondary Objective:

        -  To compare seroprotection rates against tetanus and diphtheria induced by Adacel in
           persons 10 to &lt;11 years of age to those induced by Adacel in persons 11 to &lt;12 years of
           age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will receive a single dose of study vaccine and will then be monitored for
      safety from the day of vaccination for up to 30 days post-vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of Geometric Mean Titers of Anti-Pertussis Titers Following a Single Dose of Adacel® Vaccine</measure>
    <time_frame>Day 30 post-vaccination</time_frame>
    <description>Anti-Pertussis titers (Pertussis toxoid [PT], Filamentous hemagglutinin [FHA], Pertactin [PRN], Fimbriae types 2 and 3 [FIM]) geometric mean titers were assessed by enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Anti-Pertussis Booster Response Following a Booster Dose of Adacel® Vaccine</measure>
    <time_frame>30 days post-vaccination</time_frame>
    <description>Anti-Pertussis booster responses were assessed by enzyme linked immunosorbent assay (ELISA). For pertussis antigens (Pertussis toxoid [PT], filamentous hemagglutinin [FHA], pertactin [PRN], fimbriae types 2 and 3 [FIM]), a booster response rate was defined as a four-fold increase in pre- to post-vaccination titers for participants with pre vaccination titers ≤ 93 ELISA Unit (EU)/mL for PT, ≤ 170 EU/mL for FHA, ≤ 115 EU mL for PRN, and ≤ 285 EU/mL for FIM. If the pre-vaccination titers were &gt; 93 EU/mL for PT, &gt; 170 EU/mL for FHA, &gt; 115 EU mL for PRN, or &gt; 285 EU/mL for FIM then a two-fold increase in the antibody titer was defined as a booster response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Anti-Tetanus and Anti-Diphtheria Booster Response Following a Booster Dose of Adacel® Vaccine</measure>
    <time_frame>30 days post-vaccination</time_frame>
    <description>Anti-tetanus booster responses were assessed by enzyme-linked immunosorbent assay (ELISA). Anti-diphtheria booster responses were assessed by a toxin neutralization test. Booster response rate was defined as a four-fold increase in pre- to post-vaccination for subjects with pre-vaccination titers ≤ 2.56 EU/mL for diphtheria and ≤ 2.7 EU/mL for tetanus. If the pre-vaccination titers were &gt; 2.56 EU/mL for diphtheria or &gt; 2.7 EU/mL for tetanus, then a two-fold increase in response rate was defined as a booster response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection to Tetanus and Diphtheria Following a Single Dose of Adacel Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) and 30 days post-vaccination</time_frame>
    <description>Anti-tetanus seroprotection rates were assessed by enzyme-linked immunosorbent assay (ELISA). Anti-diphtheria seroprotection was assessed by a toxin neutralization test. Seroprotection was defined as post-vaccination antibody titers ≥0.1 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Anti-Pertussis Geometric Means of Titers Before and Post-Vaccination With a Single Dose of Adacel Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 30 post-vaccination</time_frame>
    <description>Anti-Pertussis titers (Pertussis toxoid [PT], Filamentous hemagglutinin [FHA], Pertactin [PRN], Fimbriae types 2 and 3 [FIM]) geometric mean titers were assessed by enzyme linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting a Solicited Injection-site or Systemic Reactions Following Injection With a Single Dose of Adacel Vaccine</measure>
    <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
    <description>Solicited injection-site: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Headache, Malaise, and Myalgia. Grade 3 Solicited Injection-site reactions: Pain, Incapacitating, unable to perform usual activities; Erythema and Swelling, ≥50 mm. Grade 3 Solicited systemic reactions: Fever, ≥39.0˚C or ≥102.1˚F; Headache, Malaise, and Myalgia Significant, prevents daily activity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1302</enrollment>
  <condition>Tetanus</condition>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>Adacel Vaccine Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants enrolled at 10 to &lt; 11 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adacel Vaccine Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants enrolled at 11 to &lt; 12 years of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Adacel Vaccine Group 1</arm_group_label>
    <other_name>Adacel®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Adacel Vaccine Group 2</arm_group_label>
    <other_name>Adacel®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age is &gt; 10 to &lt; 12 years of age at the time of vaccination.

          -  Assent form has been signed and dated by the subject, and informed consent has been
             signed and dated by the parent(s) or another legally acceptable representative (and by
             an independent witness if required by local regulations).

          -  Subject and parent/guardian are able to attend all scheduled visits and to comply with
             all trial procedures.

          -  For a female of childbearing potential, abstinence or use of an effective method of
             contraception from at least 4 weeks prior to vaccination until at least 4 weeks after
             vaccination.

          -  Documented vaccination history of receiving 5 previous doses of DTaP (combination
             diphtheria, tetanus, and acellular pertussis) vaccine (consisting of 3 infant doses in
             the first year of life, a 4th dose in the 2nd year of life, and a 5th dose at 4
             through 6 years of age).

        Exclusion Criteria:

          -  Any condition which, in the opinion of the Investigator, would pose a health risk to
             the participant or interfere with the evaluation of the vaccine.

          -  Serious, acute, or chronic disease that is unstable or that, in the opinion of the
             Investigator, might: (i) interfere with the ability to participate fully in the study;
             or (ii) interfere with evaluation of the vaccine.

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within
             the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or
             equivalent for more than 2 consecutive weeks within the past 3 months).

          -  Prior receipt of pertussis, diphtheria, or tetanus containing vaccines within the past
             5 years.

          -  A personal history of physician-diagnosed or laboratory confirmed pertussis disease
             within the last 2 years.

          -  A previous severe reaction to pertussis, diphtheria or tetanus vaccine including
             immediate anaphylaxis, encephalopathy within 7 days or seizure within 3 days of
             receiving the vaccine.

          -  Receipt of blood or blood-derived products in the past 3 months, which might interfere
             with the assessment of the immune response.

          -  History of allergy to egg proteins, latex, or any constituents of the vaccine.

          -  Suspected or known hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccine used in the trial or to a vaccine containing
             any of the same substances.

          -  Receipt of any vaccine within 30 days before receiving study vaccine, or plans to
             receive another vaccine before the 2nd visit; except that influenza vaccine may have
             been received between 30 and 15 days (but no less than 15 days) before receiving study
             vaccine.

          -  Participation in another interventional clinical trial investigating a vaccine, drug,
             medical device, or medical procedure in the 30 days preceding the first study
             vaccination or during the course of the study.

          -  Seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C, as
             reported by the parent/guardian.

          -  Laboratory-confirmed thrombocytopenia, bleeding disorders, or receipt of
             anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular
             vaccination, at the discretion of the Investigator.

          -  Known pregnancy, or a positive urine or serum pregnancy test.

          -  Prior personal history of Guillain-Barré syndrome.

          -  Identified as an investigator or employee of the investigator or study center with
             direct involvement in the proposed study, or identified as an immediate family member
             (i.e., parent, spouse, natural or adopted child) of the investigator or employee with
             direct involvement in the proposed study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haughton</city>
        <state>Louisiana</state>
        <zip>71037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnwell</city>
        <state>South Carolina</state>
        <zip>29812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <results_first_submitted>February 2, 2016</results_first_submitted>
  <results_first_submitted_qc>April 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2016</results_first_posted>
  <disposition_first_submitted>April 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 1, 2012</disposition_first_posted>
  <last_update_submitted>April 1, 2016</last_update_submitted>
  <last_update_submitted_qc>April 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tetanus</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Tdap vaccine</keyword>
  <keyword>Adacel®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled from 07 March 2011 to 19 May 2011 at 36 clinical centers in the United States.</recruitment_details>
      <pre_assignment_details>A total of 1302 participants who met all inclusion criteria and none of the exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Participants 10 to &lt;11 Years of Age</title>
          <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
        </group>
        <group group_id="P2">
          <title>Participants 11 to &lt;12 Years of Age</title>
          <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="651"/>
                <participants group_id="P2" count="651"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="646"/>
                <participants group_id="P2" count="645"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participants 10 to &lt;11 Years of Age</title>
          <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
        </group>
        <group group_id="B2">
          <title>Participants 11 to &lt;12 Years of Age</title>
          <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="651"/>
            <count group_id="B2" value="651"/>
            <count group_id="B3" value="1302"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="651"/>
                    <measurement group_id="B2" value="651"/>
                    <measurement group_id="B3" value="1302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" spread="0.3"/>
                    <measurement group_id="B2" value="11.4" spread="0.3"/>
                    <measurement group_id="B3" value="10.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                    <measurement group_id="B2" value="315"/>
                    <measurement group_id="B3" value="620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                    <measurement group_id="B2" value="336"/>
                    <measurement group_id="B3" value="682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="651"/>
                    <measurement group_id="B2" value="651"/>
                    <measurement group_id="B3" value="1302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary of Geometric Mean Titers of Anti-Pertussis Titers Following a Single Dose of Adacel® Vaccine</title>
        <description>Anti-Pertussis titers (Pertussis toxoid [PT], Filamentous hemagglutinin [FHA], Pertactin [PRN], Fimbriae types 2 and 3 [FIM]) geometric mean titers were assessed by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 30 post-vaccination</time_frame>
        <population>Geometric mean titers were assessed in the Per-protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants 10 to &lt;11 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants 11 to &lt;12 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Geometric Mean Titers of Anti-Pertussis Titers Following a Single Dose of Adacel® Vaccine</title>
          <description>Anti-Pertussis titers (Pertussis toxoid [PT], Filamentous hemagglutinin [FHA], Pertactin [PRN], Fimbriae types 2 and 3 [FIM]) geometric mean titers were assessed by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Geometric mean titers were assessed in the Per-protocol Analysis Set.</population>
          <units>Titers (1/dilutions)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="613"/>
                <count group_id="O2" value="608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Pertussis toxoid (N=577, 566)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" lower_limit="28.0" upper_limit="32.4"/>
                    <measurement group_id="O2" value="32.0" lower_limit="29.6" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Filamentous hemagglutinin, Day 30(N=613, 608)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232" lower_limit="218" upper_limit="247"/>
                    <measurement group_id="O2" value="225" lower_limit="211" upper_limit="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pertactin (N=613, 607)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464" lower_limit="426" upper_limit="506"/>
                    <measurement group_id="O2" value="444" lower_limit="408" upper_limit="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Fimbriae types 2 &amp; 3 (N=606, 605)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477" lower_limit="413" upper_limit="550"/>
                    <measurement group_id="O2" value="540" lower_limit="478" upper_limit="611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% confidence interval (CI) was constructed around each of the ratios: Pertussis toxoid (PT) GMT Group 1 / GMT Group 2.
The GMT hypothesis was supported by the data if the lower bound of the calculated 95% CI was &gt; 0.67. This was the equivalent of testing the null hypothesis using a one-sided type I error rate of 0.025.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.940</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.843</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI was constructed around each of the ratios: anti-Filamentous hemagglutinin (FHA) GMT Group 1 / GMT Group 2.
The GMT hypothesis was supported by the data if the lower bound of the calculated 95% CI was &gt; 0.67. This was the equivalent of testing the null hypothesis using a one-sided type I error rate of 0.025.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.944</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI was constructed around each of the ratios: Anti-Pertactin (PRN) GMT Group 1 / GMT Group 2.
The GMT hypothesis was supported by the data if the lower bound of the calculated 95% CI was &gt; 0.67. This was the equivalent of testing the null hypothesis using a one-sided type I error rate of 0.025.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.928</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A two-sided 95% CI was constructed around each of the ratios: anti-Fimbriae types 2 and 3 (FIM) GMT Group 1 / GMT Group 2. The GMT hypothesis was supported by the data if the lower bound of the calculated 95% CI was &gt; 0.67. This was the equivalent of testing the null hypothesis using a one-sided type I error rate of 0.025.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.882</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.731</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Anti-Pertussis Booster Response Following a Booster Dose of Adacel® Vaccine</title>
        <description>Anti-Pertussis booster responses were assessed by enzyme linked immunosorbent assay (ELISA). For pertussis antigens (Pertussis toxoid [PT], filamentous hemagglutinin [FHA], pertactin [PRN], fimbriae types 2 and 3 [FIM]), a booster response rate was defined as a four-fold increase in pre- to post-vaccination titers for participants with pre vaccination titers ≤ 93 ELISA Unit (EU)/mL for PT, ≤ 170 EU/mL for FHA, ≤ 115 EU mL for PRN, and ≤ 285 EU/mL for FIM. If the pre-vaccination titers were &gt; 93 EU/mL for PT, &gt; 170 EU/mL for FHA, &gt; 115 EU mL for PRN, or &gt; 285 EU/mL for FIM then a two-fold increase in the antibody titer was defined as a booster response.</description>
        <time_frame>30 days post-vaccination</time_frame>
        <population>Anti-pertussis booster response were assessed in the Per-protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants 10 to &lt;11 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants 11 to &lt;12 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Anti-Pertussis Booster Response Following a Booster Dose of Adacel® Vaccine</title>
          <description>Anti-Pertussis booster responses were assessed by enzyme linked immunosorbent assay (ELISA). For pertussis antigens (Pertussis toxoid [PT], filamentous hemagglutinin [FHA], pertactin [PRN], fimbriae types 2 and 3 [FIM]), a booster response rate was defined as a four-fold increase in pre- to post-vaccination titers for participants with pre vaccination titers ≤ 93 ELISA Unit (EU)/mL for PT, ≤ 170 EU/mL for FHA, ≤ 115 EU mL for PRN, and ≤ 285 EU/mL for FIM. If the pre-vaccination titers were &gt; 93 EU/mL for PT, &gt; 170 EU/mL for FHA, &gt; 115 EU mL for PRN, or &gt; 285 EU/mL for FIM then a two-fold increase in the antibody titer was defined as a booster response.</description>
          <population>Anti-pertussis booster response were assessed in the Per-protocol Analysis Set.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="613"/>
                <count group_id="O2" value="608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Pertussis toxoid (N=554, 549)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7"/>
                    <measurement group_id="O2" value="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-filamentous hemagglutinin (N=609, 605)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2"/>
                    <measurement group_id="O2" value="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pertactin (N=600, 600)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0"/>
                    <measurement group_id="O2" value="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Fimbriae types 2 and 3 (N=583, 585)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7"/>
                    <measurement group_id="O2" value="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Anti-Tetanus and Anti-Diphtheria Booster Response Following a Booster Dose of Adacel® Vaccine</title>
        <description>Anti-tetanus booster responses were assessed by enzyme-linked immunosorbent assay (ELISA). Anti-diphtheria booster responses were assessed by a toxin neutralization test. Booster response rate was defined as a four-fold increase in pre- to post-vaccination for subjects with pre-vaccination titers ≤ 2.56 EU/mL for diphtheria and ≤ 2.7 EU/mL for tetanus. If the pre-vaccination titers were &gt; 2.56 EU/mL for diphtheria or &gt; 2.7 EU/mL for tetanus, then a two-fold increase in response rate was defined as a booster response.</description>
        <time_frame>30 days post-vaccination</time_frame>
        <population>Anti-Tetanus and anti-Diphtheria booster responses were assessed in the Per-protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants 10 to &lt;11 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants 11 to &lt;12 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Anti-Tetanus and Anti-Diphtheria Booster Response Following a Booster Dose of Adacel® Vaccine</title>
          <description>Anti-tetanus booster responses were assessed by enzyme-linked immunosorbent assay (ELISA). Anti-diphtheria booster responses were assessed by a toxin neutralization test. Booster response rate was defined as a four-fold increase in pre- to post-vaccination for subjects with pre-vaccination titers ≤ 2.56 EU/mL for diphtheria and ≤ 2.7 EU/mL for tetanus. If the pre-vaccination titers were &gt; 2.56 EU/mL for diphtheria or &gt; 2.7 EU/mL for tetanus, then a two-fold increase in response rate was defined as a booster response.</description>
          <population>Anti-Tetanus and anti-Diphtheria booster responses were assessed in the Per-protocol Analysis Set.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="613"/>
                <count group_id="O2" value="608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Tetanus (N=610, 603)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5"/>
                    <measurement group_id="O2" value="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria (N=609, 605)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7"/>
                    <measurement group_id="O2" value="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection to Tetanus and Diphtheria Following a Single Dose of Adacel Vaccine</title>
        <description>Anti-tetanus seroprotection rates were assessed by enzyme-linked immunosorbent assay (ELISA). Anti-diphtheria seroprotection was assessed by a toxin neutralization test. Seroprotection was defined as post-vaccination antibody titers ≥0.1 IU/mL.</description>
        <time_frame>Day 0 (pre-vaccination) and 30 days post-vaccination</time_frame>
        <population>Seroprotection rates were assessed in the Per Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants 10 to &lt;11 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants 11 to &lt;12 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection to Tetanus and Diphtheria Following a Single Dose of Adacel Vaccine</title>
          <description>Anti-tetanus seroprotection rates were assessed by enzyme-linked immunosorbent assay (ELISA). Anti-diphtheria seroprotection was assessed by a toxin neutralization test. Seroprotection was defined as post-vaccination antibody titers ≥0.1 IU/mL.</description>
          <population>Seroprotection rates were assessed in the Per Protocol Analysis Set.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="613"/>
                <count group_id="O2" value="608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Tetanus (Pre-vaccination, N=610, 604)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3"/>
                    <measurement group_id="O2" value="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus (Post-vaccination, N=613, 607)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria (Pre-vaccination, N=610, 605)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6"/>
                    <measurement group_id="O2" value="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria (Post-vaccination, N=612, 608)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Anti-Pertussis Geometric Means of Titers Before and Post-Vaccination With a Single Dose of Adacel Vaccine</title>
        <description>Anti-Pertussis titers (Pertussis toxoid [PT], Filamentous hemagglutinin [FHA], Pertactin [PRN], Fimbriae types 2 and 3 [FIM]) geometric mean titers were assessed by enzyme linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 0 (pre-vaccination) and Day 30 post-vaccination</time_frame>
        <population>Geometric mean titers were assessed in the Per Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants 10 to &lt;11 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants 11 to &lt;12 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Anti-Pertussis Geometric Means of Titers Before and Post-Vaccination With a Single Dose of Adacel Vaccine</title>
          <description>Anti-Pertussis titers (Pertussis toxoid [PT], Filamentous hemagglutinin [FHA], Pertactin [PRN], Fimbriae types 2 and 3 [FIM]) geometric mean titers were assessed by enzyme linked immunosorbent assay (ELISA).</description>
          <population>Geometric mean titers were assessed in the Per Protocol Analysis Set.</population>
          <units>Titers (1/dilutions)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="613"/>
                <count group_id="O2" value="608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Pertussis toxoid; Day 0 (N = 590, 591)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" lower_limit="4.54" upper_limit="5.42"/>
                    <measurement group_id="O2" value="4.85" lower_limit="4.41" upper_limit="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pertussis toxoid; Day 30 (N = 577, 566)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" lower_limit="28.0" upper_limit="32.4"/>
                    <measurement group_id="O2" value="32.0" lower_limit="29.6" upper_limit="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Filamentous hemagglutinin Day 0 (N=609, 605)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" lower_limit="20.1" upper_limit="24.2"/>
                    <measurement group_id="O2" value="20.3" lower_limit="18.5" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Filamentous hemagglutinin Day 30 (N=613, 608)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232" lower_limit="218" upper_limit="247"/>
                    <measurement group_id="O2" value="225" lower_limit="211" upper_limit="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pertactin; Day 0 (N = 600, 601)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="14.2" upper_limit="17.1"/>
                    <measurement group_id="O2" value="14.8" lower_limit="13.5" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Pertactin; Day 30 (N = 613, 607)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464" lower_limit="426" upper_limit="506"/>
                    <measurement group_id="O2" value="444" lower_limit="408" upper_limit="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Fimbriae types 2 and 3; Day 0 (N = 590, 587)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.77" lower_limit="6.05" upper_limit="7.57"/>
                    <measurement group_id="O2" value="7.07" lower_limit="6.33" upper_limit="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Fimbriae types 2 and 3; Day 30 (N = 606, 605)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477" lower_limit="413" upper_limit="550"/>
                    <measurement group_id="O2" value="540" lower_limit="478" upper_limit="611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting a Solicited Injection-site or Systemic Reactions Following Injection With a Single Dose of Adacel Vaccine</title>
        <description>Solicited injection-site: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Headache, Malaise, and Myalgia. Grade 3 Solicited Injection-site reactions: Pain, Incapacitating, unable to perform usual activities; Erythema and Swelling, ≥50 mm. Grade 3 Solicited systemic reactions: Fever, ≥39.0˚C or ≥102.1˚F; Headache, Malaise, and Myalgia Significant, prevents daily activity.</description>
        <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
        <population>Solicited injection site and systemic reactions were assessed in the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants 10 to &lt;11 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants 11 to &lt;12 Years of Age</title>
            <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting a Solicited Injection-site or Systemic Reactions Following Injection With a Single Dose of Adacel Vaccine</title>
          <description>Solicited injection-site: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Headache, Malaise, and Myalgia. Grade 3 Solicited Injection-site reactions: Pain, Incapacitating, unable to perform usual activities; Erythema and Swelling, ≥50 mm. Grade 3 Solicited systemic reactions: Fever, ≥39.0˚C or ≥102.1˚F; Headache, Malaise, and Myalgia Significant, prevents daily activity.</description>
          <population>Solicited injection site and systemic reactions were assessed in the Safety Analysis Set.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="650"/>
                <count group_id="O2" value="649"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection-site Pain (N=644, 645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9"/>
                    <measurement group_id="O2" value="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain (N=644, 645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (N=644, 645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4"/>
                    <measurement group_id="O2" value="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema (N=644, 645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (N=644, 645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling (N=644, 645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N=642, 644)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (N=642, 644)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=644, 646)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1"/>
                    <measurement group_id="O2" value="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (N=644, 646)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N=644, 646)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (N=644, 646)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=644, 645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1"/>
                    <measurement group_id="O2" value="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (N=644, 645)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 up to Day 30 post-vaccination</time_frame>
      <desc>Solicited (non serious) adverse events were recorded in diary cards by the study participants or their guardians within 7 days after vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Participants 10 to &lt;11 Years of Age</title>
          <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
        </group>
        <group group_id="E2">
          <title>Participants 11 to &lt;12 Years of Age</title>
          <description>Participants received 1 dose of Adacel® vaccine at Visit 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="651"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="521" subjects_at_risk="651"/>
                <counts group_id="E2" subjects_affected="522" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site Pain</sub_title>
                <counts group_id="E1" events="521" subjects_affected="521" subjects_at_risk="651"/>
                <counts group_id="E2" events="522" subjects_affected="522" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Injection-site Erythema</sub_title>
                <counts group_id="E1" events="254" subjects_affected="254" subjects_at_risk="651"/>
                <counts group_id="E2" events="248" subjects_affected="248" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Injection-site Swelling</sub_title>
                <counts group_id="E1" events="227" subjects_affected="227" subjects_at_risk="651"/>
                <counts group_id="E2" events="216" subjects_affected="216" subjects_at_risk="651"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="169" subjects_affected="169" subjects_at_risk="651"/>
                <counts group_id="E2" events="189" subjects_affected="189" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="316" subjects_affected="316" subjects_at_risk="651"/>
                <counts group_id="E2" events="364" subjects_affected="364" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="213" subjects_affected="213" subjects_at_risk="651"/>
                <counts group_id="E2" events="243" subjects_affected="243" subjects_at_risk="651"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

